Evotec SE (ETR:EVT)
Germany · Delayed Price · Currency is EUR | Market Cap | 908.30M -28.9% |
| Revenue (ttm) | 745.04M -5.5% |
| Net Income | -193.88M |
| EPS | -1.09 |
| Shares Out | 177.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,013,420 |
| Open | 5.20 |
| Previous Close | 5.11 |
| Day's Range | 5.12 - 5.31 |
| 52-Week Range | 4.00 - 7.84 |
| Beta | 1.30 |
| Analysts | Buy |
| Price Target | 6.44 (+21.97%) |
| Earnings Date | Aug 13, 2026 |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c... [Read more]
Full Company ProfileFinancial Performance
In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.
Financial StatementsNews
EQS-DD: Evotec SE: Dr. Cord Dohrmann, sell
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 22.05.2026 / 14:00 CET/CEST The issuer is solely responsi...
Evotec SE (EVO) Issues â¬116.1M Convertible Bonds to Support Project Horizon
Evotec SE (EVO) Issues â¬116.1M Convertible Bonds to Support Project Horizon
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO...
EQS-Adhoc: Evotec SE launches approximately EUR 125 million convertible bond offering
EQS-Ad-hoc: Evotec SE / Key word(s): Capital measures / Other Evotec SE launches approximately EUR 125 million convertible bond offering 12-May-2026 / 17:45 CET/CEST Disclosure of an inside informatio...
EQS-DD: Evotec SE: Paul Hitchin, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.05.2026 / 13:43 CET/CEST The issuer is solely responsi...
EQS-DD: Evotec SE: Aurélie Dalbiez, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.05.2026 / 13:41 CET/CEST The issuer is solely responsi...
EQS-DD: Evotec SE: Dr. Christian Wojczewski, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.05.2026 / 13:39 CET/CEST The issuer is solely responsi...
EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2025 pursuant Evotec’s remuneration system.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.05.2026 / 13:37 CET/CEST The issuer is solely responsi...
EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evotec SE Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 05.05.202...
Evotec (EVO) Advances Preclinical Development Candidate in Dermatology
Evotec (EVO) Advances Preclinical Development Candidate in Dermatology
Evotec nominates first preclinical development candidate from Almirall pact
Evotec (EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance in medical dermatology with Almirall. The program is aimed at ...
Evotec SE: Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelinesCollaboration leverages Evotec's end-to-end integrated A...
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Joint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelines Collaboration leverages Evotec's end-to-end integrated AI/...
Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development
Evotec (EVO) Secures Funds from Gates Foundation for TB Drug Development
Evotec receives two grants for tuberculosis drug discovery, translation
Evotec (EVO) announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis, following four earlier TB grants from the foundation, amounting to…
Evotec SE: Evotec Receives Grants to Advance Tuberculosis Treatment
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testingNew funding from the Gates Foundation extends Evote...
Evotec Receives Grants to Advance Tuberculosis Treatment
Grants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing New funding from the Gates Foundation extends Evotec'...
Evotec SE: Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilitiesConclusion of cooperation agreement with MAK Capital following ...
Evotec Announces New Nomination to Board of Directors
Nomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilities Conclusion of cooperation agreement with MAK Capital following co...
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
HAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2...
Evotec CFO Paul Hitchin to step down, Claire Hinshelwood to succeed
Evotec (EVO) announced that CFO Paul Hitchin will step down on April 30 for personal reasons unrelated to the company. The supervisory board has accepted Hitchin’s decision. Hitchin will be…
Evotec CFO Paul Hitchin Resigns; Names Claire Hinshelwood Replacement
(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced Friday that its CFO Paul Hitchin will leave the company on April 30, "citing personal reasons unrelated to Evotec."
Evotec Announces Chief Financial Officer Transition
Paul Hitchin to step down as of April 30, 2026 Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standa...
Evotec assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Evotec (EVO) with a Buy rating and $7 price target The company’s has transformed from a legacy asset-heavy integrated model toward a leaner and capital-efficient…
Evotec appoints Ingrid Muller as COO
Evotec (EVO) announced the appointment of Ingrid Muller as COO. Muller will be joining Evotec’s management board, effective May 1. In her role as COO, Muller will oversee Evotec’s global…